UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE and Wyeth in Pharmacogenomics Collaboration
deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced the...
deCODE Generates First X-ray based, 3-D Image of How Important Anti-cancer Drug Works
Highlights deCODE’s capabilities in structural biology and x-ray protein crystallography; may enable design of more effective anti-cancer compounds Reykjavik, ICELAND, November 11, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced that scientists from...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.